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ABSTRACT
Background and Objectives: The EPIC™ stent is a self-expanding, nitinol stent that has been 
designed to enhance flexibility and provide expansion within vessels. The aim of the present 
study was to investigate the clinical efficacy and safety of the EPIC™ stent when used to treat 
iliac artery diseases in a prospective Korean multicenter registry.
Methods: A total of 138 patients with iliac artery diseases who received endovascular 
treatment with EPIC™ stents at 9 Korean sites were enrolled in a prospective cohort 
and followed for 1 year. The primary endpoint was the 1-year freedom from target lesion 
revascularization (TLR). The secondary endpoints were 1-year clinical patency and freedom 
from major adverse events (MAEs).
Results: The mean age of the study subjects was 66.8±8.5 years and most subjects were 
male (86.2%). The most frequent lesion type was Trans-Atlantic Inter-Society Consensus 
B (43.5%) and the majority (56.5%) of the target lesions were located in the common iliac 
artery. Procedural success was obtained in 99.3% of patients. The freedom from TLR and 
the clinical patency at 1-year follow-up were 94.9% and 92.3%, respectively. The 1-year rate of 
MAEs was 5.1%. Combined coronary artery disease (hazard ratio [HR], 5.91; 95% confidence 
interval [CI], 1.13–30.89; p=0.035) and smaller stent diameter (HR, 0.38; 95% CI, 0.17–0.88; 
p=0.023) were identified as independent risk factors of TLR after EPIC™ stent implantation.
Conclusions: The EPIC™ stents demonstrated excellent immediate and 1-year efficacy and 
safety outcomes in iliac artery lesions in this multicenter, prospective, registry-based study.
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INTRODUCTION
Endovascular therapy (EVT) has been widely applied in the treatment of peripheral artery 
diseases (PADs) due to its minimal invasiveness and lower perioperative morbidity compared 
with surgical treatment.1-3) Atherosclerotic aortoiliac disease is commonly observed in 
patients undergoing EVT for symptomatic lower extremity artery disease.4) In a recent 
guideline, EVT was recommended as a first-line treatment strategy not only for short 
aortoiliac lesions but also for extensive lesions in patients with severe comorbidities.3) 
Although both primary and provisional stenting may achieve similar results in patients with 
limited aortoiliac lesions, primary stenting may provide superior outcomes for complex 
aortoiliac lesions.3)5) Currently, several different types of stents such as self-expanding, 
balloon-expanding, and covered stents are available for the treatment of aortoiliac lesions. 
However, there is limited information comparing the effectiveness of these devices.6) Iliac 
artery lesions tend to be tortuous and calcified. In particular, distal external iliac artery 
lesions are exposed to forces related to the movement of the hip joint.7) The EPIC™ stent 
(Boston Scientific, Natick, MA, USA) is a self-expanding nitinol stent with a hybrid design of 
open and closed cell structures that may enhance its flexibility and conformational dilation 
capability.8) The purpose of the present study was to investigate the clinical efficacy and 
safety of the EPIC™ stent in the treatment of iliac artery diseases using a Korean multicenter 
prospective registry (K-EPIC Registry).
METHODS
Study population and enrollment
This study was a single-arm, prospective, multicenter trial evaluating the EPIC™ self-expanding 
nitinol stent in the treatment of atherosclerotic iliac artery diseases. The trial was conducted 
in 9 sites in South Korea following the Declaration of Helsinki 2013. The study protocol was 
approved by the Institutional Review Board (IRB) of Yonsei University Health System (IRB 
number: 1-2015-0075). All patients provided written informed consent before enrollment.
Patients were eligible if all following inclusion criteria were met, such as age ≥19 years, 
clinical presentation of Rutherford category 2 to 4, stenotic (≥50% diameter stenosis) or 
occlusive iliac artery lesions, and an ankle-brachial index (ABI) <0.9. Exclusion criteria 
included acute severe limb ischemia, severe critical limb ischemia of Rutherford category 5 or 
6, age >85 years, known allergic reactions to heparin, aspirin, clopidogrel, or contrast agent, 
in-stent restenosis, previous bypass surgery in the targeted vessel, uncontrolled congestive 
heart failure or left ventricular ejection fraction ≤40%, severe hepatic dysfunction (aspartate 
transaminase or alanine aminotransferase ≥3-fold higher than the normal reference value), 
significant leukopenia, neutropenia, thrombocytopenia, anemia, or risk of bleeding, 
pregnant or fertile women, life expectancy under 1 year, and non-treated significant inflow 
disease. Before enrollment, each patient's medical history, baseline medications, Rutherford 
classification, Korean-Peripheral Artery Questionnaire (K-PAQ)9) for the investigation of 
quality of life, ABI, at least one imaging study such as computed tomography (CT), magnetic 
resonance imaging, duplex ultrasound, or catheter angiography and Trans-Atlantic Inter-
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Society Consensus (TASC) II type assessment, laboratory tests including blood cell count, 
routine chemistry, lipid profile, and C-reactive protein were performed.
K-PAQ is the Korean version of the Peripheral Artery Questionnaire of 20-item health status 
used for patients with PAD. Each question asks about symptoms related to PAD over the 
previous 4 weeks. The questionnaire consists of 6 domains (symptoms, symptom stability, 
physical limitations, treatment satisfaction, social functioning, and quality of life) with 
scored responses. A summary score represents the average score for symptoms, physical 
limitation, social functioning, and quality of life. The scores range from 0 to 100, where 
higher scores represent better control of symptoms, reduced physical limitation, better 
treatment satisfaction and social functioning, and better quality of life.
Endovascular and therapy
Before the procedure, patients were pre-medicated with aspirin (300 mg, at least 24 hours 
prior) and clopidogrel (300 mg, at least 12 hours prior) if patients had not taken aspirin and 
clopidogrel for at least 5 days before the procedure. After the insertion of the introducer 
sheath, a bolus of 5,000 units of unfractionated heparin was administrated and activated 
coagulation time was maintained above 250 seconds.
Vascular access to the target lesion was obtained by either the ipsilateral retrograde or the 
contralateral cross-over approach from the common femoral artery, using a percutaneous 
method. An antegrade approach via a brachial or radial artery was also permitted if necessary. 
A 6–7 F sheath (TERUMO Inc., Tokyo, Japan) was used on the ipsilateral approach and a 6–7 
F sheath (Balkin or Ansel; Cook Inc., Bloomington, IN, USA) was used on the contralateral 
approach. To cross the target lesion, a 0.018 or 0.035-inch guidewire was used. To evaluate 
the characteristics of the iliac artery lesion and runoff vessels, pre-procedure angiography 
was obtained from the proximal iliac artery to the distal tibial artery. In cases of complete 
occlusion, an intraluminal or subintimal approach was selected at the operator's discretion. 
Target lesions were pre-dilated with a balloon catheter to a diameter equal-to or smaller-
than the reference diameter. All iliac target lesions were treated with EPIC™ stents. The 
stent diameter was chosen to be 1 mm larger than the target lesion reference diameter. The 
stent length was selected to be sufficient to cover the whole diseased segment. Post-dilation 
was performed with a balloon of vessel diameter at a relatively low inflation pressure. After 
EVT, dual antiplatelet agents (aspirin at 100 mg/day and clopidogrel at 75 mg/day) were 
administrated for at least 6 months. After 6 months, single antiplatelet therapy with aspirin 
or clopidogrel was maintained.
Follow-up
After EVT, patients were evaluated for symptom status via Rutherford classification and 
ABI, and laboratory tests were performed. Patients were followed-up routinely at 1 month 
after the procedure and 3- or 6-month intervals thereafter. At each follow-up, clinical 
evaluations including Rutherford classification and physical examinations were performed. 
ABI was repeated at 6 months and 1 year after the procedure, or at any time if symptom 
status deteriorated. K-PAQ was performed at the 1-month and 1-year follow-up. An imaging 
evaluation such as CT angiography, duplex ultrasound, or intra-arterial angiography was 
recommended at the 1-year follow-up or at any time if the patient's symptoms worsened by ≥1 




The primary endpoint was the 1-year freedom from target lesion revascularization (TLR), 
which was defined as any surgical or percutaneous intervention to the target lesion after 
initial EVT due to restenosis of the target lesion with worsened symptoms. The secondary 
endpoints were a 1-year clinical patency rate and freedom from major adverse events (MAEs) 
after implantation of EPIC™ stents. Clinical patency was defined as freedom from symptom 
aggravation by increased Rutherford category combined with a decrease in ABI over 0.15 
compared with post-procedure ABI or as an absence of restenosis (>50%) on imaging 
modalities, such as duplex ultrasound, angiography, or CT based angiography. MAE was 
defined as a composite of procedure-related death within one month, in-hospital myocardial 
infarction, TLR, and amputation of the treated limb. Procedural success was defined as the 
absence of residual stenosis more than 30% or arterial dissection limiting blood flow.
Statistical analysis
Continuous variables are presented as the mean±standard deviation, and categorical variables 
are presented as frequency and percentage. Baseline clinical and lesion characteristics were 
analyzed using the Student's t-test for continuous data and χ2 and Fisher's exact test for 
categorical data. The one-way analysis of variance was used for comparisons of K-PAQ scores 
at baseline, 1 month, and 1 year of follow-up.
Freedom from TLR, clinical patency, and MAE were assessed using the Kaplan-Meier method 
and a log-rank test was used to compare each group. The predictors of TLR were evaluated 
using a univariate and multivariate analyses of the Cox proportional hazard regression. All 
variables with p<0.15 in univariate analysis were included in the multivariate analysis model.
A p value <0.05 was considered significant. All statistical analyses were performed using 
SPSS 25.0 software (IBM Corp., Armonk, NY, USA).
RESULTS
Study population
Initially, a total of 150 patients were enrolled at 9 university hospitals in South Korea between 
December 2015 to July 2018. However, 12 patients were excluded due to pre-specified criteria 
(Rutherford category 0 or 1 [n=6], Rutherford category 5 or 6 [n=3], congestive heart failure 
[n=1], non-treated aortic lesion [n=1], and withdrawal of consent [n=1]). The remaining 138 
patients were included in the present analysis (Figure 1). The baseline clinical characteristics 
of the study subjects are summarized in Table 1. The mean age was 66.8±8.5 years and most 
patients were male (86.2%). Hypertension and diabetes were present in 75.4% and 50.0% of 
the study subjects, respectively. Coronary artery disease was observed in 33.3% of patients. 
The most common clinical presentation in the study subjects was severe claudication 
(68.1%). The mean ABI in the target limb was 0.60±0.30.
Lesion characteristics
Table 2 shows the lesion characteristics of all patients. The most frequent lesion type was 
TASC B (n=60, 43.5%), followed by the TASC A (n=41, 29.7%), TASC C (n=22, 15.9%), and 
TASC D (n=15, 10.9%). The majority (56.5%) of target lesions were located in the common 
iliac artery (CIA). Extensive lesions involving both the common and external iliac arteries 
were observed in 15.9% of patients. Total occlusion was found in 39.1% of patients. Pre-
444https://e-kcj.org https://doi.org/10.4070/kcj.2020.0420
K-EPIC Registry
dilation was performed in all patients. The mean stent diameter was 8.8±1.0 mm. Post-
dilation was required in 77.5% of patients.
Immediate outcomes
Procedural success was obtained in 137 of the 138 patients (99.3%). The one procedural 














A total of 138 patients were
included for analysis
Mortality at 2 months
(n=1, cardiac death)
Mortality at 12 months
(n=1, non-cardiac death)
Figure 1. Patient flowchart.
Table 1. Baseline patient characteristics
Characteristics Total (n=138)
Age (years) 66.8±8.5







Current smoker 55 (39.9)












Baseline ABI in the target limb 0.60±0.30
Data are presented as mean±standard deviation or number (%).
ABI = ankle-brachial index; BMI = body mass index; CKD = chronic kidney disease; DM = diabetes mellitus; ESRD = 
end state renal disease; HTN = hypertension; NOAC = new oral anticoagulants.
Procedure-related complications occurred in 2 patients (1.4%). One patient showed distal 
embolization to the ipsilateral popliteal artery, which was successfully treated by thrombus 
aspiration. Another patient experienced perforation of the CIA during the procedure, which 
was successfully managed by prolonged balloon inflation.
Clinical outcomes at 1-year follow-up
Of the 138 patients included in this study, 136 patients completed the 1-year clinical follow-
up. An imaging follow-up at 12 months was performed in 46 patients (33.3%). Clinical 
symptom assessment using K-PAQ was followed in 130 patients (94.2%). One patient died at 
2 months due to a cardiovascular complication after TLR by bypass surgery. Another patient 
died at 8 months due to sepsis. The freedom from TLR was 94.9% at 1 year (Figure 2A). 
Among 7 patients who required TLR, 6 patients underwent endovascular revascularization 
and 1 patient received bypass surgery. The 1-year clinical patency was 92.3% (Figure 2B). 
The 1-year rate of freedom from MAE was 94.9% (Figure 2C). Within 1 month, there was no 
mortality, in-hospital myocardial infarction, or target limb amputation. All 7 MAEs were 
related to TLR within 1 year.
When TASC lesion types A/B and C/D were compared, the freedom from TLR (90.4% vs. 
94.4%, log-rank p=0.456, Figure 3A) as well as the clinical patency (91.7% vs. 94.1%, log-rank 
p=0.628, Figure 3B) showed no significant difference between the 2 subgroups. Patients' 
symptom status, expressed as Rutherford category at baseline, post-procedure, 6 months, 
and 12 months are shown in Figure 4. Before the procedure, all patients (n=138) had either 
intermittent claudication (Rutherford class 2–3, n=121) or rest pain (Rutherford class 4, 
n=17). After the EVT, 67 patients (48.6%) were asymptomatic (Rutherford class 0) and the 
proportion of asymptomatic patients further increased to 64.7% at 6 months and 72.1% at 12 
months. Health status expressed as K-PAQ at baseline, 1 month, and 12 months are shown in 
Supplementary Table 1. The summary score at baseline was 40.9±23.1 and was significantly 
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Common to EIA 22 (15.9)
Combined lesion
Iliac artery only 83 (60.1)
Femoropopliteal artery 42 (30.4)
BTK 6 (4.3)
Femoropopliteal artery & BTK 7 (5.1)
Total occlusion 54 (39.1)
Lesion length (mm) 54.3±30.0
Mean stent diameter (mm) 8.8±1.0
Mean stent length (mm) 60.4±22.5
Number of stent (per lesion) 1.2±0.5
Post-dilation 107 (77.5)
Data are presented as mean±standard deviation or number (%).
BTK = below-the-knee; CIA = common iliac artery; EIA = external iliac artery; TASC = Trans-Atlantic Inter-Society 
Consensus.
improved to 74.2±24.7 at 1 month and 82.3±23.2 at 12 months. All K-PAQ domains (except the 
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Figure 2. Kaplan-Meier curves for clinical outcomes of all patients. 
MAE = major adverse event; PTA = percutaneous transluminal angioplasty; TLR = target lesion revascularization.
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Figure 3. Kaplan-Meier curves for clinical outcomes in patients with TASC A/B and C/D.  
PTA = percutaneous transluminal angioplasty; TASC = Trans-Atlantic Inter-Society Consensus; TLR = target lesion 
revascularization.
Predictors for TLR
In univariate analyses, a history of coronary artery disease, smaller stent diameter, and longer 
stent length was significantly associated with increased risk of TLR. The multivariate analysis 
of the Cox proportional hazard model identified the history of coronary artery disease 
(hazard ratio [HR], 5.91; 95% confidence interval [CI], 1.13–30.89; p=0.035) and smaller 
stent diameter (HR, 0.38; 95% CI, 0.17–0.88; p=0.023) as significant independent predictors 

















































Figure 4. Rutherford class at baseline as well as post-procedure, 6 months, and 12 months after endovascular 
treatment for aortoiliac occlusive diseases.
Table 3. Predictors of TLR
Variables
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Male 0.96 (0.12–7.93) 0.966
Age (years) 1.01 (0.92–1.10) 0.905
BMI (kg/m2) 0.92 (0.73–1.17) 0.515
HTN 1.97 (0.24–16.36) 0.530
DM 1.33 (0.30–5.92) 0.712
CKD 2.23 (0.27–18.50) 0.459
Dyslipidemia 1.70 (0.38–7.60) 0.486
Current smoker 2.04 (0.46–9.13) 0.350
Coronary artery disease 5.27 (1.02–27.15) 0.047 5.91 (1.13–30.89) 0.035
Stroke 0.91 (0.11–7.60) 0.934
Previous PTA 2.03 (0.39–10.46) 0.398
Target lesion ABI 0.66 (0.06–7.24) 0.732
Rutherford category 0.51 (0.14–1.89) 0.310
TASC C/D 0.44 (0.05–3.68) 0.450
Combined lesions 1.11 (0.25–4.98) 0.887
Chronic total occlusion 1.19 (0.27–5.30) 0.824
Lesion length (mm) 1.00 (0.98–1.03) 0.754
Mean stent diameter (mm) 0.42 (0.19–0.94) 0.034 0.38 (0.17–0.88) 0.023
Mean stent length (mm) 1.03 (1.00–1.06) 0.032 1.01 (0.99–1.04) 0.338
Total number of stents 0.63 (0.09–4.75) 0.657
ABI = ankle-brachial index; BMI = body mass index; CI = confidence interval; CKD = chronic kidney disease; DM = 
diabetes mellitus; HR = hazard ratio; HTN = hypertension; PTA = percutaneous transluminal angioplasty; TASC = 
Trans-Atlantic Inter-Society Consensus; TLR = target lesion revascularization.
DISCUSSION
This prospective registry study evaluated clinical outcomes in patients treated with EPIC™ 
self-expanding stents for iliac lesions and evaluated risk factors to predict TLR. The main 
findings of the present study were as follows: 1) The EPIC™ stent showed excellent clinical 
outcomes in terms of freedom from TLR (94.9%) and clinical patency (92.3%) at 1-year of 
follow-up. 2) The incidence of procedure-related complications was rare (1.4%). 3) The 1-year 
rate of MAE also remained low (5.1%). 4) In our study population, combined coronary artery 
disease and smaller stent diameter were identified as independent risk factors of TLR after 
EPIC™ stent implantation in the iliac artery lesions. 5) The lesion complexity, such as TASC 
C/D, had no apparent impact on patency after EVT.
In a prior randomized trial, the first generation nitinol stent (SMART™; Cordis, Warren, 
NJ, USA) demonstrated comparable primary patency (94.7% vs. 94.6%) in iliac lesions at 
12 months compared with Wallstent™, a braided Elgiloy stainless steel stent.10) However, 
the procedural success rate of the SMART™ stent was significantly higher than that of the 
Wallstent™, at 98.2% and 87.5%, respectively. Owing to the characteristic properties of 
nitinol, such as shape memory and superelasticity,11) self-expanding nitinol stents appear 
to be effective for maintaining patency in complex aortoiliac lesions by preventing vessel 
collapse and ensuring stability. Other studies evaluating nitinol stents such as Protégé stents 
(Medtronic, Plymouth, MN, USA) and the Astron stent (Biotronik AG, Bülach, Switzerland) 
have also reported favorable outcomes in the treatment of iliac artery disease. The 9-month 
primary patency and freedom from the target for Protégé stents in the DURABILITY study 
were 95.8% and 98.6%, respectively. The 12-month primary patency and freedom from 
TLR for the Astron stent were 89.8% and 97.9%, respectively.12) The EPIC™ stent is a self-
expanding nitinol stent with a hybrid design of open- and closed-cell geometry engineered to 
provide flexibility. The efficacy and safety of the EPIC™ stent have been previously evaluated 
in the ORION trial, a single-arm prospective multicenter clinical trial, which enrolled 125 
patients with 166 iliac artery lesions in 28 sites in the USA. At the 12-month follow-up, the 
freedom from the TLR rate was 94.6% and the primary patency was 94.4%.13) A Japanese 
multicenter retrospective study also investigated the clinical outcomes of the EPIC™ stent in 
aortoiliac artery disease and reported similar 12-month rates of freedom from TLR (96.0%) 
and primary patency (92.2%).8) Our study demonstrated results that were consistent with 
those previous studies. Similarly to our study, the ORION study did not show a significant 
difference in the primary patency rate between the TASC A/B group vs. TASC C/D group 
(96.1% and 97.6%).13)
The efficacy of self-expanding stents was shown in a randomized controlled study comparing 
self-expanding stents vs. balloon-expandable stents for iliac artery disease.14) In this study, 
the self-expanding stents showed superior outcomes in terms of primary patency (94.5% vs. 
87.0%) and freedom from TLR (97.2% vs. 93.6%) relative to balloon-expandable stents.
Predictable factors of revascularization after the implantation of nitinol stents in iliac 
artery lesions have been analyzed in several studies. Tsujimura et al.8) reported that diabetes 
mellitus and a small reference vessel diameter were predictors of lesion patency. In the 
BRAVISSIMO study,15) kissing stent technique and obesity were independent risk factors for 
restenosis. Interestingly, Bechter-Hugl et al.16) found that younger age, especially in female 
patients, was a significant predictor of restenosis, as was a smaller stent diameter. Our study 
also found that a small stent diameter (HR, 0.38; p=0.023) was an independent risk factor 
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for TLR. Furthermore, coronary artery disease was another independent risk factor for TLR 
(HR, 5.91; p=0.035) in our study. The reason for the significant association between coronary 
artery disease and the development of restenosis after iliac stenting remains unclear. It is 
possible that patients with polyvascular disease, involving more than one vascular system, 
would have more progressed atherosclerosis than PAD alone, and would be high-risk patients 
to develop restenosis after revascularization. Previous studies have shown that polyvascular 
atherosclerotic disease in PAD patients is associated with increased rates of mortality, major 
adverse cardiac events, and lower extremity revascularization.17)18)
This study had several limitations. First, the study population was relatively small. In 
particular, subjects with complex iliac artery lesions such as TASC C or D were not 
sufficiently represented. Second, follow-up imaging studies such as CT angiography, 
vascular angiography, or Doppler ultrasound were not consistently performed in all patients, 
potentially contributing to bias. We defined primary clinical patency as freedom from 
symptom aggravation with an ABI decrease >0.15 or absence of restenosis on imaging 
studies. Thus, restenosis without causing an ABI decrease >0.15 or related symptoms may 
have been undetected, and the primary patency rate may have been overestimated. Third, the 
duration of clinical follow-up in this study was only one year, which may be not sufficient to 
evaluate the efficacy of stents in iliac arteries.
In conclusion, in a multicenter prospective registry study, the EPIC™ stent demonstrated 
excellent immediate and 1-year efficacy and safety in patients with iliac artery disease.
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